Related references
Note: Only part of the references are listed.Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies
Anthony Stonehouse et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study
R. Ratner et al.
DIABETIC MEDICINE (2010)
Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study
Veronika Vlckova et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2010)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study
Michael A. Nauck et al.
DIABETES CARE (2009)
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes
G. Derosa et al.
DIABETES OBESITY & METABOLISM (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes
Jochen Seufert et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1
Jocelyn de Heer et al.
DIABETES (2007)
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
B Charbonnel et al.
DIABETOLOGIA (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study
DR Matthews et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Share Paper
